Concepedia

David Stock

DS

27

Publications

3K

Citations

22

H-Index

1969

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Biohaven Pharmaceuticals (United States)

Albert Einstein College of Medicine

King's College London

Wellcome Trust

David Stock is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

1969–2023

27

Publications

27

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Robert Croop, Peter J. Goadsby, David Stock et al. · The Lancet · 2019 · 379 citations

, , +5

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

Richard B. Lipton, Robert Croop, Elyse Stock et al. · New England Journal of Medicine · 2019 · 379 citations · Full text

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Robert Croop, Richard B. Lipton, David Kudrow et al. · The Lancet · 2020 · 334 citations

, , +7

BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

Ronald N. Marcus, Peter J. Goadsby, David W. Dodick et al. · Cephalalgia · 2013 · 285 citations

4-Thiazolidinones: novel inhibitors of the bacterial enzyme murB

Charles J. Andres, Joanne J. Bronson, Stanley V. D’Andrea et al. · Bioorganic & Medicinal Chemistry Letters · 2000 · 218 citations

, , +6

Rows per page

1–5 of 27